poisar

Stocks · News reference

Ascentage Pharma Announces Trustee Share Purchase for RSU Scheme

Fiscal.ai

Ascentage Pharma announced that its trustee purchased 200,000 shares in the open market to fulfill obligations under its 2022 Restricted Share Unit (RSU) scheme.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAscentage Pharma Group International

    Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

    Ascentage Pharma announced that lisaftoclax has been included in China's 2026 National Reimbursement Drug List (NRDL) for treating chronic lymphocytic leukemia/small lymphocytic lymphoma, while olverembatinib successfully renewed its NRDL coverage for chronic myeloid leukemia treatment. Both approvals take effect January 1, 2027, and represent all approved indications for both drugs now being covered by the NRDL, significantly improving patient access and affordability in China.